EZEttore Zapparoli

Ettore Zapparoli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ettore Zapparoli has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel role of the lncRNA EPR as oncosuppressor in intestinal cancer

    by N Shim, M Rossi, M Nicolau, Jr Barajas, E Zapparoli, P Briata, Pl Puri, R Gherzi, L Caputo

    We previously reported that the murine lncRNA Epr is essential for maintaining colon mucosal integrity and permeability. Mice lacking Epr in the colon are more susceptible to colitis and tumor development. Additionally, we demonstrated that human EPR expression is reduced in ulcerative colitis and in a small cohort of colon adenocarcinoma patients. Here, we present evidence that human and mouse EPR share several key physiological features: preferential binding to the KH1 domain of their interacting protein, KSRP; specific expression in canonical and immature goblet cells of the large intestine; and a functional role in intestinal goblet cell development. The correlation between EPR levels and survival in large cohorts of metastatic colon adenocarcinoma patients, together with the capacity of human EPR to inhibit cell proliferation and induce apoptosis in two distinct human colon adenocarcinoma cell lines, suggests that EPR may serve as both a valuable prognostic marker for goblet cell-derived adenocarcinomas and a potential therapeutic target.

  • Open Access

    Effects of introgressed Neanderthal alleles on present-day brain morphology

    by Roberta Zeloni, Alessandro Amaolo, Adeline Morez Jacobs, Ettore Zapparoli, Yara Akl, Mahan Shafie, Emilia Huerta-Sanchez, Fabrizio Pizzagalli, Paolo Provero, Luca Pagani, et al.

    Neanderthal introgression contributed a small fraction of genetic variants to present-day non-African genomes. While differences in cranial globularity between Neanderthal and modern humans are well documented from endocasts, the phenotypic consequences of these introgressed alleles can illuminate otherwise inaccessible genetically divergent brain structures. We analyzed 370 MRI-derived brain traits—including cortical and subcortical regional measurements, cortical folding metrics, diffusion tracts—in nearly 40,000 UK Biobank participants. To quantify the impact of Neanderthal ancestry, we intersected trait-associated loci with Neanderthal-derived variants identified from introgressed segments imputed in the same subjects. Low-frequency introgressed variants were depleted for detectable effects on brain phenotypes, whereas common introgressed variants showed no comparable depletion. Conversely, Neanderthal deserts were consistently enriched for functional effects. Eight associations were fine-mapped to Neanderthal-derived variants: one locus near the gene DAAM1 was especially prominent across multiple traits, including opposite effects in the cuneus and precuneus mediated by introgressed regulatory variants. Genome-wide directional alignment of Neanderthal effects was limited but became evident when focusing on suggestive loci: frontal and parietal areas were the most consistently affected traits, though not in a direction that obviously mirrors known modern-archaic morphology divergence. Several of these loci also influenced neuropsychiatric traits, with detectable polygenic consequences against schizophrenia and towards major depression, linking neuroanatomical and neuropsychiatric impact of Neanderthal introgression. These findings suggest that while introgressed alleles affecting divergent neuroanatomy between modern humans and Neanderthals were largely purged, a subset of tolerated alleles continues to shape human brain morphology and mental health.


  • Open Access

    Imputed transcriptional patterns in ancient genomes reveal molecular targets of selection

    by Mathilde André, Francesco Montinaro, Ettore Zapparoli, Paolo Provero, Davide Marnetto

    The genetically regulated component of molecular traits can be imputed from ancient genomes, though low genotyping quality and genetic drift may impair accurate expression prediction and results interpretation. We developed tissue-specific gene expression and alternative splicing prediction models and applied them to over a thousand imputed ancient genomes spanning 10,000 years of Western Eurasian history. We revealed gene regulatory patterns diverging with time, space and genomic ancestry by fitting predicted transcriptional profiles onto multivariable models including these factors. By interpreting associations with time as recent natural selection we identify hits mediated by transcriptional changes. Finally, we fine-mapped these selection signals to tissue-specific transcriptional traits, explicitly accounting for prediction uncertainty. Among others, we elucidate the spatial patterns and the regulatory features promoting selection at LCT, FADS1, SLC22A5/ P4HA2, ACAD10 / OAS3 and find novel signals of selection at TBIMB6, SORD2P and AC012370 . 3 .

  • Open Access

    Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL

    by Sarka Pavlova, Jitka Malcikova, Lenka Radova, Silvia Bonfiglio, Jack B. Cowland, Christian Brieghel, Mette K. Andersen, Maria Karypidou, Bella Biderman, Michael Doubek, et al.

    In chronic lymphocytic leukemia, the reliability of next‐generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low‐VAF) is debated. We tested the ability to detect 23 such variants in 41 different laboratories using their NGS method of choice. The sensitivity was 85.6%, 94.5%, and 94.8% at 1%, 2%, and 3% VAF cut‐off, respectively. While only one false positive (FP) result was reported at >2% VAF, it was more challenging to distinguish true variants TP53 variants had shorter TTST and OS versus wt‐TP53 patients, and the relative risk of second‐line treatment or death increased continuously with increasing VAF. Targeted therapy in ≥2 line diminished the difference in OS between patients with low‐VAF TP53 variants and wt‐TP53 patients, while patients with high‐VAF TP53 variants had inferior OS compared to wild type‐TP53 cases. Altogether, NGS‐based approaches are technically capable of detecting low‐VAF variants. No strict threshold can be suggested from a technical standpoint, laboratories reporting TP53 mutations should participate in a standardized validation set‐up. Finally, whereas low‐VAF variants affected outcomes in patients receiving chemoimmunotherapy, their impact on those treated with novel therapies remains undetermined. Our results pave the way for the harmonized and accurate TP53 assessment, which is indispensable for elucidating the role of TP53 mutations in targeted treatment.


  • Open Access

    SP140 represses specific loci by recruiting polycomb repressive complex 2 and NuRD complex

    by Simone Tamburri, Chiara Zucchelli, Vittoria Matafora, Ettore Zapparoli, Zivojin Jevtic, Francesco Farris, Fabio Iannelli, Giovanna Musco, Angela Bachi

    SP140, a lymphocytic-restricted protein, is an epigenetic reader working as a corepressor of genes implicated in inflammation and orchestrating macrophage transcriptional programs to maintain cellular identity. Reduced SP140 expression is associated both to autoimmune diseases and blood cancers. However, the molecular mechanisms that link SP140 altered protein levels to detrimental effects on the immune response and cellular growth, as well as the interactors through which SP140 promotes gene silencing, remain elusive. In this work, we have applied a multi-omics approach (i.e. interactomics, ChIP-seq and proteomics) in two Burkitt lymphoma cell lines to identify both interactors and target genes of endogenous SP140. We found that SP140 interacts with the PRC2 and NuRD complexes, and we showed that these interactions are functional as SP140 directs H3K27me3 deposition and NuRD binding on a set of target genes implicated in cellular growth and leukemia progression.


  • Open Access

    PML modulates epigenetic composition of chromatin to regulate expression of pro-metastatic genes in triple-negative breast cancer

    by Cristina Fracassi, Martina Ugge', Mohamed Abdelhalim, Ettore Zapparoli, Matilde Simoni, Daniela Magliulo, Davide Mazza, Dejan Lazarevic, Marco J Morelli, Philippe Collas, et al.

    The promyelocytic leukemia (PML) protein organizes nuclear aggregates known as PML nuclear bodies (PML-NBs), where many transcription factors localize to be regulated. In addition, associations of PML and PML-NBs with chromatin are described in various cell types, further implicating PML in transcriptional regulation. However, a complete understanding of the functional consequences of PML association to DNA in cellular contexts where it promotes relevant phenotypes is still lacking. We examined PML chromatin association in triple-negative breast cancer (TNBC) cell lines, where it exerts important oncogenic functions. We find that PML associates discontinuously with large heterochromatic PML-associated domains (PADs) that contain discrete gene-rich euchromatic sub-domains locally depleted of PML. PML promotes heterochromatic organization in PADs and expression of pro-metastatic genes embedded in these sub-domains. Importantly, this occurs outside PML-NBs, suggesting that nucleoplasmic PML exerts a relevant gene regulatory function. We also find that PML plays indirect regulatory roles in TNBC cells by promoting the expression of pro-metastatic genes outside PADs. Our findings suggest that PML is an important transcriptional regulator of pro-oncogenic metagenes in TNBC cells, via transcriptional regulation and epigenetic organization of heterochromatin domains that embed regions of local transcriptional activity.


  • Open Access

    LncRNAEPRregulates intestinal mucus production and protects against inflammation and tumorigenesis

    by Paola Briata, Luca Mastracci, Ettore Zapparoli, Luca Caputo, Elisa Ferracci, Alessandra Silvestri, Anna Garuti, Meriem Hadjer Hamadou, Alberto Inga, Elisa Marcaccini, et al.

    The long non-coding RNA EPR is expressed in epithelial tissues, binds to chromatin and controls distinct biological activities in mouse mammary gland cells. Because of its high expression in the intestine, in this study we have generated a colon-specific conditional targeted deletion (EPR cKO) to evaluate EPR in vivo functions in mice. EPR cKO mice display epithelium hyperproliferation, impaired mucus production and secretion, as well as inflammatory infiltration in the proximal portion of the large intestine. RNA sequencing analysis reveals a rearrangement of the colon crypt transcriptome with strong reduction of goblet cell-specific factors including those involved in the synthesis, assembly, transport and control of mucus proteins. Further, colon mucosa integrity and permeability are impaired in EPR cKO mice, and this results in higher susceptibility to dextran sodium sulfate (DSS)-induced colitis and tumor formation. Human EPR is down-regulated in human cancer cell lines as well as in human cancers, and overexpression of EPR in a colon cancer cell line results in enhanced expression of pro-apoptotic genes. Mechanistically, we show that EPR directly interacts with select genes involved in mucus metabolism whose expression is reduced in EPR cKO mice and that EPR deletion causes tridimensional chromatin organization changes.


  • Open Access

    LncRNA EPR-induced METTL7A1 modulates target gene translation

    by Paola Briata, Luca Caputo, Ettore Zapparoli, Elisa Marcaccini, Mario Passalacqua, Lorenzo Brondolo, Domenico Bordo, Annalisa Rossi, Chiara Nicoletti, Gabriele Bucci, et al.

    EPR is a long non-coding RNA (lncRNA) that controls cell proliferation in mammary gland cells by regulating gene transcription. Here, we report on Mettl7a1 as a direct target of EPR. We show that EPR induces Mettl7a1 transcription by rewiring three-dimensional chromatin interactions at the Mettl7a1 locus. Our data indicate that METTL7A1 contributes to EPR-dependent inhibition of TGF-β signaling. METTL7A1 is absent in tumorigenic murine mammary gland cells and its human ortholog (METTL7A) is downregulated in breast cancers. Importantly, re-expression of METTL7A1 in 4T1 tumorigenic cells attenuates their transformation potential, with the putative methyltransferase activity of METTL7A1 being dispensable for its biological functions. We found that METTL7A1 localizes in the cytoplasm whereby it interacts with factors implicated in the early steps of mRNA translation, associates with ribosomes, and affects the levels of target proteins without altering mRNA abundance. Overall, our data indicates that METTL7A1—a transcriptional target of EPR—modulates translation of select transcripts.


  • Open Access

    Comprehensive multi-omics analysis uncovers a group of TGF-β-regulated genes among lncRNA EPR direct transcriptional targets

    by Ettore Zapparoli, Paola Briata, Martina Rossi, Lorenzo Brondolo, Gabriele Bucci, Roberto Gherzi

    Long non-coding RNAs (lncRNAs) can affect multiple layers of gene expression to control crucial cellular functions. We have previously demonstrated that the lncRNA EPR, by controlling gene expression at different levels, affects cell proliferation and migration in cultured mammary gland cells and impairs breast tumor formation in an orthotopic transplant model in mice. Here, we used ChIRP-Seq to identify EPR binding sites on chromatin of NMuMG mammary gland cells overexpressing EPR and identified its trans binding sites in the genome. Then, with the purpose of relating EPR/chromatin interactions to the reshaping of the epitranscriptome landscape, we profiled histone activation marks at promoter/enhancer regions by ChIP-Seq. Finally, we integrated data derived from ChIRP-Seq, ChIP-Seq as well as RNA-Seq in a comprehensive analysis and we selected a group of bona fide direct transcriptional targets of EPR. Among them, we identified a subset of EPR targets whose expression is controlled by TGF-β with one of them—Arrdc3—being able to modulate Epithelial to Mesenchymal Transition. This experimental framework allowed us to correlate lncRNA/chromatin interactions with the real outcome of gene expression and to start defining the gene network regulated by EPR as a component of the TGF-β pathway.


  • Open Access

    Total Binding Affinity Profiles of Regulatory Regions Predict Transcription Factor Binding and Gene Expression in Human Cells

    by Elena Grassi, Ettore Zapparoli, Ivan Molineris, Paolo Provero

    Transcription factors regulate gene expression by binding regulatory DNA. Understanding the rules governing such binding is an essential step in describing the network of regulatory interactions, and its pathological alterations. We show that describing regulatory regions in terms of their profile of total binding affinities for transcription factors leads to increased predictive power compared to methods based on the identification of discrete binding sites. This applies both to the prediction of transcription factor binding as revealed by ChIP-seq experiments and to the prediction of gene expression through RNA-seq. Further significant improvements in predictive power are obtained when regulatory regions are defined based on chromatin states inferred from histone modification data.